SIBRAFIBAN VS ASPIRIN PROTECTION FROM ISCHEMIC HEART EVENTS
SIBRAFIBAN VS ASPIRIN PROTECTION FROM ISCHEMIC HEART EVENTS
批准号:
6264452
负责人:
THOMAS VROBEL
金额:
$1.92万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Symphony Trial- Sibrafiban vs. aspirin to yield maximum protection from ischemic heart events post acute coronary syndromes is a multi-center drug trial comparing the efficacy of Sibrafiban, an oral platelet glycoprotein IIb/IIIa antagonist to aspirin as therapy for the prevention of secondary vascular events in patients after an acute coronary syndrome. This study is now closed to recruitment and the next phase is a phase III double blind study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GUARD DURING ISCHEMIA AGAINST NECROSIS (GUARDIAN)
-
批准号:6264461
-
项目类别:
-
资助金额:$1.92万
-
财政年份:1998
-
负责人:THOMAS VROBEL
-
依托单位:
SIBRAFIBAN VS ASPIRIN PROTECTION FROM ISCHEMIC HEART EVENTS
-
批准号:6305392
-
项目类别:
-
资助金额:$1.92万
-
财政年份:--
-
负责人:THOMAS VROBEL
-
依托单位:
GUARD DURING ISCHEMIA AGAINST NECROSIS (GUARDIAN)
-
批准号:6305401
-
项目类别:
-
资助金额:$1.92万
-
财政年份:--
-
负责人:THOMAS VROBEL
-
依托单位:
海外基金